Pipeline

Scandion Oncology is building a pipeline of drugs that can revert cancer drug resistance through different mechanisms

---

Our Clinical Pipeline

Scandion Oncology has two programs in clinical development with our first-in-class lead compound SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is a clinical phase II study. The second program, PANTAX, for the treatment of unresectable or metastatic pancreatic cancer is a clinical phase Ib study.

Our Pre-clinical Pipeline

Scandion Oncology is building a pre-clinical pipeline of drugs that can revert cancer drug resistance through different mechanisms, to increasingly broaden the offering of medicines able to combat various types of cancer drug resistance.